ImmuCell 2025 Net Loss Narrows Y/Y as Sales & Margins Improve

Core Viewpoint - ImmuCell Corporation reported improved financial performance for the year ended December 31, 2025, with significant operational improvements and a strategic focus on its First Defense product line, despite facing some challenges in the fourth quarter. Financial Performance - For the year 2025, ImmuCell reported product sales of $27.6 million, a 4.3% increase from $26.5 million in 2024 [2] - The net loss narrowed to $1 million, or 12 cents per basic share, from a net loss of $2.2 million, or 26 cents per basic share, in the prior year [2] - Gross margin expanded to 41.4% of product sales in 2025 from 30% in 2024, reflecting operational improvements and stronger sales volumes [2] Operating Metrics - Gross profit reached $11.4 million for the year, up from $7.9 million in 2024, driven by improved production volumes and manufacturing efficiencies [3] - Operating income turned positive with net operating income of $1.6 million in 2025, compared to an operating loss of $1.6 million in the previous year, representing an improvement of $3.3 million [4] Quarterly Performance - In the fourth quarter, product sales were $7.6 million, down 1.6% from $7.75 million in the same quarter last year [5] - Domestic sales increased by 8.7% year over year to approximately $7 million, while international sales declined to about $600,000 due to order timing issues [5] Operating Expenses - Total operating expenses rose to $9.8 million in 2025 from $9.6 million in 2024, primarily due to higher general and administrative costs [6] Balance Sheet - ImmuCell ended the year with $3.8 million in cash and cash equivalents, unchanged from 2024 [7] - Net working capital increased to approximately $13 million from $10.6 million, attributed to higher finished goods inventory levels [7] Management Commentary - Management characterized 2025 as a successful year, emphasizing operational improvements and strategic changes, particularly focusing on the First Defense franchise [8] - The company increased manufacturing output, boosting average monthly production from approximately 345,000 units in 2024 to about 380,000 units in 2025 [9] Market Fundamentals - The calf health market is expanding, with U.S. producers spending approximately $93 million on scours prevention products in 2025, a 14% increase from 2024 [10] - A significant portion of calves still receive no treatment, indicating a large addressable market opportunity [10] Strategic Outlook - The company expects manufacturing improvements to support continued sales growth in 2026 and 2027, with plans to increase production capacity to 5-6 million units annually [14] - ImmuCell is strengthening its commercial operations by adding sales personnel and hiring an international market development leader to accelerate customer outreach [15] Strategic Developments - The company decided to shift focus away from the Re-Tain product program, pausing investment in it to prioritize the First Defense franchise [16] - Certain Re-Tain-related assets were written down and are expected to be repurposed to support First Defense production [17] Overall Assessment - The 2025 results reflect operational progress, improved margins, and a clearer strategic focus, although near-term profitability is influenced by restructuring-related charges and ongoing investments [18]